Identification of a potent and selective noncovalent cathepsin S inhibitor

被引:50
作者
Thurmond, RL [1 ]
Sun, SQ [1 ]
Sehon, CA [1 ]
Baker, SM [1 ]
Cai, H [1 ]
Gu, Y [1 ]
Jiang, W [1 ]
Riley, JP [1 ]
Williams, KN [1 ]
Edwards, JP [1 ]
Karlsson, L [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA USA
关键词
D O I
10.1124/jpet.103.056879
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cathepsin S is considered crucial for normal presentation of major histocompatibility complex (MHC) class II-restricted antigens by antigen presenting cells to CD4(+) T cells. It is a key enzyme for the degradation of the class II-associated invariant chain, a process that is required for effective antigen loading of class II molecules. Here, we report a selective, orally available, high-affinity cathepsin S inhibitor, 1-[3-[4-(6-Chloro-2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl] propyl]-4,5,6,7-tetrahydro-5-(methylsulfonyl)-3-[4-(trifluoromethyl) phenyl]-1H-pyrazolo[4,3-c] pyridine. (JNJ 10329670), that represents a novel class of immunosuppressive compounds. JNJ 10329670 is a highly potent (K-i of similar to30 nM), nonpeptidic, noncovalent inhibitor of human cathepsin S, but it is much less active against the mouse, dog, monkey, and bovine enzymes. The compound is inactive against other proteases, including the closely related cathepsins L, F, and K. This selectivity makes JNJ 10329670 an excellent tool for exploring the role of cathepsin S in human systems. Treatment of human B cell lines and primary human dendritic cells with JNJ 10329670 resulted in the accumulation of the p10 fragment of the invariant chain (IC50 of similar to1 muM). In contrast, inhibition of invariant chain proteolysis was much less effective in a human monocytic cell line, suggesting that other enzymes may degrade the invariant chain in this cell type. JNJ 10329670 was shown to block the proteolysis of the invariant chain in vivo by using immunocompromised mice injected with human peripheral blood mononuclear cells (PBMCs). Furthermore, this inhibitor blocks the presentation of tetanus toxoid and giant ragweed by human PBMCs. The properties of JNJ 10329670 make it a candidate for immunosuppressive therapy of allergies and autoimmune diseases.
引用
收藏
页码:268 / 276
页数:9
相关论文
共 23 条
[1]   THE EFFECT OF SOME ANTIINFLAMMATORY AGENTS ON ELASTASE RELEASE FROM NEUTROPHILS INVITRO [J].
ADEYEMI, EO ;
CHADWICK, VS ;
HODGSON, HJF .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1990, 42 (07) :487-490
[2]   THE ENDOTHELIN-CONVERTING ENZYME FROM HUMAN UMBILICAL VEIN IS A MEMBRANE-BOUND METALLOPROTEASE SIMILAR TO THAT FROM BOVINE AORTIC ENDOTHELIAL-CELLS [J].
AHN, K ;
BENINGO, K ;
OLDS, G ;
HUPE, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (18) :8606-8610
[3]  
Allen E. M., 2001, Inflammation Research, V50, pS159
[4]   Cloning, expression, purification, and activity of dog (Canis familiaris) and monkey (Saimiri boliviensis) cathepsin S [J].
Baker, SM ;
Karlsson, L ;
Thurmond, RL .
PROTEIN EXPRESSION AND PURIFICATION, 2003, 28 (01) :93-101
[5]  
Biroc SL, 2001, ARTHRITIS RHEUM, V44, P703, DOI 10.1002/1529-0131(200103)44:3<703::AID-ANR120>3.0.CO
[6]  
2-2
[7]  
BUTLER CR, 2002, Patent No. 0214315
[8]   Endosomal proteolysis and MHC class II function [J].
Chapman, HA .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (01) :93-102
[9]   Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells [J].
Fiebiger, E ;
Meraner, P ;
Weber, E ;
Fang, IF ;
Stingl, G ;
Ploegh, H ;
Maurer, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (08) :881-892
[10]   MONOCROTALINE PYRROLE-INDUCED CHANGES IN ANGIOTENSIN-CONVERTING ENZYME-ACTIVITY OF CULTURED PULMONARY-ARTERY ENDOTHELIAL-CELLS [J].
HOORN, CM ;
ROTH, RA .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (02) :597-602